The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Atherosclerotic cardiovascular disease (ASCVD) is the world’s leading cause of death. ASCVD has multiple mediators that therapeutic interventions target, such as dyslipidaemia, hypertension, diabetes and heightened systemic inflammatory tone, among others. LDL cholesterol is one of the most well-studied and established mediators targeted for primary and secondary prevention of ASCVD. However, despite the strength of evidence supporting LDL cholesterol reduction by multiple management strategies, ASCVD events can still recur, even in patients whose LDL cholesterol has been very aggressively reduced. Hypertriglyceridaemia and elevated levels of triglyceride-rich lipoproteins (TRLs) may be key contributors to ASCVD residual risk. Several observational and genetic epidemiological studies have highlighted the causal role of triglycerides within the TRLs and/or their remnant cholesterol in the development and progression of ASCVD. TRLs consist of intestinally derived chylomicrons and hepatically synthesised very LDL. Lifestyle modification has been considered the first line intervention for managing hypertriglyceridaemia. Multiple novel targeted therapies are in development, and have shown efficacy in the preclinical and clinical phases of study in managing hypertriglyceridaemia and elevated TRLs. This comprehensive review provides an overview of the biology, pathogenicity, epidemiology, and genetics of triglycerides and TRLs, and how they impact the risk for ASCVD. In addition, we provide a summary of currently available and novel emerging triglyceride-lowering therapies in development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Besides LDL-C, hypertriglyceridaemia is thought to contribute to development and progression of atherosclerotic coronary plaques”
From Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis (2024) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885 · cited 1×
“34 It has been studied as a potential target for managing TRL abnormalities.”
Background
Research works printed but not linked: 70
- Rosenson RS, Shaik A, Song W. New therapies for lowering triglyceride-rich lipoproteins: JACC focus Seminar 3/4. J Am Coll Cardiol 2021;78:1817–30. https://doi.org/10.1016/j.jacc.2021.08.051; PMID: 34711341. · DOI · Paper page
- Jarcho JA, Keaney Jr JF. Proof that lower is better – LDL cholesterol and IMPROVE-IT. N Engl J Med 2015;372:2448–50. https://doi.org/10.1056/NEJMe1507041; PMID: 26039520. · DOI · Paper page
- Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32:1345–61. https://doi.org/10.1093/eurheartj/ehr112; PMID: 21531743. · DOI
- Xiao C, Hsieh J, Adeli K, Lewis GF. Gut-liver interaction in triglyceride-rich lipoprotein metabolism. Am J Physiol Endocrinol Metab 2011;301:E429–46. https://doi.org/10.1152/ajpendo.00178.2011; PMID: 21693689. · DOI · Paper page
- Zheng C. Updates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease. Curr Opin Lipidol 2014;25:35–9. https://doi.org/10.1097/MOL.0000000000000040; PMID: 24345989. · DOI · Paper page
- Ginsberg HN. Lipoprotein physiology. Endocrinol Metab Clin North Am 1998;27:503–19. https://doi.org/10.1016/s0889-8529(05)70023-2; PMID: 9785050. · DOI · Paper page
- Goldstein JL, Ho YK, Brown MS, et al. Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolemic canine beta-very low density lipoproteins. J Biol Chem 1980;255:1839–48. https://doi.org/10.1016/S0021-9258(19)85958-6; PMID: 7354064. · DOI · Paper page
- Gower RM, Wu H, Foster GA, et al. CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol 2011;31:160–6. https://doi.org/10.1161/ATVBAHA.110.215434; PMID: 21030716. · DOI · Paper page
- Hua S. Targeting sites of inflammation: intercellular adhesion molecule-1 as a target for novel inflammatory therapies. Front Pharmacol 2013;4:127. https://doi.org/10.3389/fphar.2013.00127; PMID: 24109453. · DOI · Paper page
- Alipour A, van Oostrom AJ, Izraeljan A, et al. Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler Thromb Vasc Biol 2008;28:792–7. https://doi.org/10.1161/ATVBAHA.107.159749; PMID: 18218988. · DOI · Paper page
- Zheng XY, Liu L. Remnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthase. J Lipid Res 2007;48:1673–80. https://doi.org/10.1194/jlr.R700001-JLR200; PMID: 17496332. · DOI · Paper page
- Sol EM, Sundsten T, Bergsten P. Role of MAPK in apolipoprotein CIII-induced apoptosis in INS-1E cells. Lipids Health Dis 2009;8:3. https://doi.org/10.1186/1476-511X-8-3; PMID: 19196457. · DOI
- Kones R. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag 2013;9:617–70. https://doi.org/10.2147/VHRM.S37119; PMID: 24174878. · DOI
- Mailly F, Tugrul Y, Reymer PW, et al. A common variant in the gene for lipoprotein lipase (Asp9-->Asn). Functional implications and prevalence in normal and hyperlipidemic subjects. Arterioscler Thromb Vasc Biol 1995;15:468–78. https://doi.org/10.1161/01.atv.15.4.468; PMID: 7749858. · DOI · Paper page
- Jukema JW, van Boven AJ, Groenemeijer B, et al. The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. Circulation 1996;94:1913–8. https://doi.org/10.1161/01.cir.94.8.1913; PMID: 8873668. · DOI · Paper page
- Liu X, Li J, Liao J, et al. Gpihbp1 deficiency accelerates atherosclerosis and plaque instability in diabetic Ldlr(-/-) mice. Atherosclerosis 2019;282:100–9. https://doi.org/10.1016/j.atherosclerosis.2019.01.025; PMID: 30721842. · DOI
- Wulff AB, Nordestgaard BG, Tybjærg-Hansen A. APOC3 loss-of-function mutations, remnant cholesterol, low-density lipoprotein cholesterol, and cardiovascular risk: mediation- and meta-analyses of 137 895 individuals. Arterioscler Thromb Vasc Biol 2018;38:660–8. https://doi.org/10.1161/ATVBAHA.117.310473; PMID: 29348120. · DOI · Paper page
- Liu Y, Xu J, Tao W, et al. A compound heterozygous mutation of lipase maturation Factor 1 is responsible for hypertriglyceridemia of a patient. J Atheroscler Thromb 2019;26:136–44. https://doi.org/10.5551/jat.44537; PMID: 29910226. · DOI
- Varbo A, Benn M, Tybjærg-Hansen A, et al. TRIB1 and GCKR polymorphisms, lipid levels, and risk of ischemic heart disease in the general population. Arterioscler Thromb Vasc Biol 2011;31:451–7. https://doi.org/10.1161/ATVBAHA.110.216333; PMID: 21071687. · DOI · Paper page
- Zannis VI. Genetic polymorphism in human apolipoprotein E. Methods Enzymol 1986;128:823–51. https://doi.org/10.1016/0076-6879(86)28109-4; PMID: 3724530. · DOI
- Lahoz C, Schaefer EJ, Cupples LA, et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 2001;154:529–37. https://doi.org/10.1016/s0021-9150(00)00570-0; PMID: 11257253. · DOI · Paper page
- Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996;97:2917–23. https://doi.org/10.1172/JCI118751; PMID: 8675707. · DOI · Paper page
- Gómez P, Miranda JL, Marín C, et al. Influence of the −514C/T polymorphism in the promoter of the hepatic lipase gene on postprandial lipoprotein metabolism. Atherosclerosis 2004;174:73–9. https://doi.org/10.1016/j.atherosclerosis.2003.12.038; PMID: 15135253. · DOI
- Zambon A, Deeb SS, Pauletto P, et al. Hepatic lipase: a marker for cardiovascular disease risk and response to therapy. Curr Opin Lipidol 2003;14:179–89. https://doi.org/10.1097/00041433-200304000-00010; PMID: 12642787. · DOI · Paper page
- Stanford KI, Wang L, Castagnola J, et al. Heparan sulfate 2-O-sulfotransferase is required for triglyceride-rich lipoprotein clearance. J Biol Chem 2010;285:286–94. https://doi.org/10.1074/jbc.M109.063701; PMID: 19889634. · DOI · Paper page
- Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993;88:2762–70. https://doi.org/10.1161/01.cir.88.6.2762; PMID: 8252689. · DOI · Paper page
- McNamara JR, Shah PK, Nakajima K, et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 2001;154:229–36. https://doi.org/10.1016/s0021-9150(00)00484-6; PMID: 11137104. · DOI · Paper page
- Imke C, Rodriguez BL, Grove JS, et al. Are remnant-like particles independent predictors of coronary heart disease incidence? The Honolulu Heart study. Arterioscler Thromb Vasc Biol 2005;25:1718–22. https://doi.org/10.1161/01.ATV.0000173310.85845.7b; PMID: 15947240. · DOI · Paper page
- Varbo A, Benn M, Smith GD, et al. Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as mediators from obesity to ischemic heart disease. Circ Res 2015;116:665–73. https://doi.org/10.1161/CIRCRESAHA.116.304846; PMID: 25411050. · DOI · Paper page
- Varbo A, Freiberg JJ, Nordestgaard BG. Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population. Clin Chem 2015;61:533–43. https://doi.org/10.1373/clinchem.2014.234146; PMID: 25605681. · DOI · Paper page
- Saeed A, Feofanova EV, Yu B, et al. Remnant-like particle cholesterol, low-density lipoprotein triglycerides, and incident cardiovascular disease. J Am Coll Cardiol 2018;72:156–69. https://doi.org/10.1016/j.jacc.2018.04.050; PMID: 29976289. · DOI · Paper page
- Wadström BN, Wulff AB, Pedersen KM, et al. Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study. Eur Heart J 2022;43:3258–69. https://doi.org/10.1093/eurheartj/ehab705; PMID: 34661640. · DOI · Paper page
- Chevli PA, Islam T, Pokharel Y, et al. Association between remnant lipoprotein cholesterol, high-sensitivity C-reactive protein, and risk of atherosclerotic cardiovascular disease events in the Multi-Ethnic Study of Atherosclerosis (MESA). J Clin Lipidol 2022;16:870–7. https://doi.org/10.1016/j.jacl.2022.09.005; PMID: 36180367. · DOI
- Huh JH, Han KD, Cho YK, et al. Remnant cholesterol and the risk of cardiovascular disease in type 2 diabetes: a nationwide longitudinal cohort study. Cardiovasc Diabetol 2022;21:228. https://doi.org/10.1186/s12933-022-01667-6; PMID: 36324177. · DOI · Paper page
- Yoshida H, Ito K, Manita D, et al. Clinical significance of intermediate-density lipoprotein cholesterol determination as a predictor for coronary heart disease risk in middle-aged men. Front Cardiovasc Med 2021;8:756057. https://doi.org/10.3389/fcvm.2021.756057; PMID: 34881308. · DOI
- Yang N, Wang M, Liu J, et al. The level of remnant cholesterol and implications for lipid-lowering strategy in hospitalized patients with acute coronary syndrome in China: findings from the improving care for cardiovascular disease in China-acute coronary syndrome project. Metabolites 2022;12:898. https://doi.org/10.3390/metabo12100898; PMID: 36295800. · DOI
- Varbo A, Nordestgaard BG. Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction. Eur Heart J 2021;42:4833–43. https://doi.org/10.1093/eurheartj/ehab293; PMID: 34023898. · DOI · Paper page
- Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 – executive summary. J Clin Lipidol 2014;8:473–88. https://doi.org/10.1016/j.jacl.2014.07.007; PMID: 25234560. · DOI · Paper page
- Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237–45. https://doi.org/10.1056/NEJM198711123172001; PMID: 3313041. · DOI · Paper page
- Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs high-density lipoprotein cholesterol intervention trial study group. N Engl J Med 1999;341:410–8. https://doi.org/10.1056/NEJM199908053410604; PMID: 10438259. · DOI · Paper page
- Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002;301:1042–51. https://doi.org/10.1124/jpet.301.3.1042; PMID: 12023536. · DOI · Paper page
- Larsen ML, Illingworth DR, O’Malley JP. Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia. Atherosclerosis 1994;106:235–40. https://doi.org/10.1016/0021-9150(94)90128-7; PMID: 8060383. · DOI
- Syvänne M, Vuorinen-Markkola H, Hilden H, Taskinen MR. Gemfibrozil reduces postprandial lipemia in non-insulin-dependent diabetes mellitus. Arterioscler Thromb 1993;13:286–95. https://doi.org/10.1161/01.atv.13.2.286; PMID: 8427863. · DOI · Paper page
- Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000;102:21–7. https://doi.org/10.1161/01.cir.102.1.21; PMID: 10880410. · DOI · Paper page
- Kazama H, Usui S, Okazaki M, et al. Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes. Diabetes Res Clin Pract 2003;59:181–9. https://doi.org/10.1016/s0168-8227(02)00243-7; PMID: 12590014. · DOI
- Ohno Y, Miyoshi T, Noda Y, et al. Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study. Cardiovasc Diabetol 2014;13:71. https://doi.org/10.1186/1475-2840-13-71; PMID: 24708775. · DOI
- Ikewaki K, Tohyama J, Nakata Y, et al. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men – a nuclear magnetic resonance study. J Atheroscler Thromb 2004;11:278–85. https://doi.org/10.5551/jat.11.278; PMID: 15557710. · DOI · Paper page
- Min YJ, Choi YH, Hyeon CW, et al. Fenofibrate reduces C-reactive protein levels in hypertriglyceridemic patients with high risks for cardiovascular diseases. Korean Circ J 2012;42:741–6. https://doi.org/10.4070/kcj.2012.42.11.741; PMID: 23236325. · DOI
- Sano K, Nakamura T, Hirano M, et al. Comparative study of bezafibrate and pravastatin in patients with coronary artery disease and high levels of remnant lipoprotein. Circ J 2010;74:1644–50. https://doi.org/10.1253/circj.cj-10-0079; PMID: 20574136. · DOI
- Blair HA, Dhillon S. Omega-3 carboxylic acids (Epanova): a review of its use in patients with severe hypertriglyceridemia. Am J Cardiovasc Drugs 2014;14:393–400. https://doi.org/10.1007/s40256-014-0090-3; PMID: 25234378. · DOI
- Innes JK, Calder PC. Marine Omega-3 (N-3) Fatty Acids for Cardiovascular Health: an update for 2020. Int J Mol Sci 2020;21:1362. https://doi.org/10.3390/ijms21041362; PMID: 32085487. · DOI · Paper page
- Myran L, Nguyen TN. Icosapent ethyl (Vascepa) for hyperlipidemia/hypercholesterolemia to reduce risk of heart attack and stroke. Am Fam Phys 2021;103:117–8. PMID: 33448769.
- Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA 2020;324:2268–80. https://doi.org/10.1001/jama.2020.22258; PMID: 33190147. · DOI · Paper page
- Ando M, Sanaka T, Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol 1999;10:2177–84. https://doi.org/10.1681/ASN.V10102177; PMID: 10505695. · DOI · Paper page
- Ferri N, Corsini A, Sirtori C, Ruscica M. PPAR-α agonists are still on the rise: an update on clinical and experimental findings. Expert Opin Investig Drugs 2017;26:593–602. https://doi.org/10.1080/13543784.2017.1312339; PMID: 28343425. · DOI · Paper page
- Yamashita S, Arai H, Yokote K, et al. Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia. J Clin Lipidol 2018;12:1267-79.e4. https://doi.org/10.1016/j.jacl.2018.06.010; PMID: 30077640. · DOI · Paper page
- Rosenson RS, Rader D, Ali S, et al. Evinacumab reduces remnant cholesterol in patients with hypercholesterolemia or hypertriglyceridemia. Atherosclerosis 2022;355:223. https://doi.org/10.1016/j.atherosclerosis.2022.06.874. · DOI
- Paik J, Duggan S. Volanesorsen: first global approval. Drugs 2019;79:1349–54. https://doi.org/10.1007/s40265-019-01168-z; PMID: 31301033. · DOI · Paper page
- Blom DJ, O’Dea L, Digenio A, et al. Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study. J Clin Lipidol 2018;12:1234–1243.e5. https://doi.org/10.1016/j.jacl.2018.05.013; PMID: 30318066. · DOI · Paper page
- Tardif JC, Karwatowska-Prokopczuk E, Amour ES, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J 2022;43:1401–12. https://doi.org/10.1093/eurheartj/ehab820; PMID: 35025993. · DOI · Paper page
- Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013;381:40–6. https://doi.org/10.1016/S0140-6736(12)61731-0; PMID: 23122768. · DOI · Paper page
- Nohara A, Otsubo Y, Yanagi K, et al. Safety and efficacy of lomitapide in Japanese patients with homozygous familial hypercholesterolemia (HoFH): results from the AEGR-733-301 long-term extension study. J Atheroscler Thromb 2019;26:368–77. https://doi.org/10.5551/jat.45708; PMID: 30259883. · DOI
- Marais AD. Apolipoprotein E and atherosclerosis. Curr Atheroscler Rep 2021;23:34. https://doi.org/10.1007/s11883-021-00933-4; PMID: 33970359. · DOI
- Wittrup HH, Tybjaerg-Hansen A, Abildgaard S, et al. A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease. J Clin Invest 1997;99:1606–13. https://doi.org/10.1172/JCI119323; PMID: 9120004. · DOI · Paper page
- Surendran RP, Visser ME, Heemelaar S, et al. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J Intern Med 2012;272:185–96. https://doi.org/10.1111/j.1365-2796.2012.02516.x; PMID: 22239554. · DOI · Paper page
- Davison PJ, Stalenhoef AF, Humphries SE. Apolipoprotein CII (apo CII) gene expression defect in an individual with familial apo CII deficiency. Biochem Biophys Res Commun 1987;148:320–8. https://doi.org/10.1016/0006-291x(87)91113-2; PMID: 2445343. · doi:10.1016/0006-291x(87)91113-2
- Gerber Y, Goldbourt U, Cohen H, Harats D. Association between serum apolipoprotein C(II) concentration and coronary heart disease. Prev Med 2002;35:42–7. https://doi.org/10.1006/pmed.2002.1045; PMID: 12079439. · DOI
- Jiao X, Yang Y, Li L, et al. Angiopoietin-like protein 8 accelerates atherosclerosis in ApoE-/- mice(-/). Atherosclerosis 2020;307:63–71. https://doi.org/10.1016/j.atherosclerosis.2020.06.014; PMID: 32739681. · DOI
- Voyvodic PL, Min D, Liu R, et al. Loss of syndecan-1 induces a pro-inflammatory phenotype in endothelial cells with a dysregulated response to atheroprotective flow. J Biol Chem 2014;289:9547–59. https://doi.org/10.1074/jbc.M113.541573; PMID: 24554698. · DOI
- Mabuchi H, Nohara A, Inazu A. Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors. Mol Cells 2014;37:777–84. https://doi.org/10.14348/molcells.2014.0265; PMID: 25410905. · DOI
Cited by
Dinu, M., Sofi, F., Lotti, S., Colombini, B., Mattioli, A. V., Catapano, A. L., Casula, M., Baragetti, A., Wong, N. D., Steg, P. G., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae184 · Cited by 43
Xiong, C.-C., Gao, F., Zhang, J.-H., Ruan, Y., Gao, T.-G., Cai, J.-Y., & Liu, S.-F. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.131946 · Cited by 39
Metadata
- Authors
- Gabani, M., Shapiro, M. D., & Toth, P. P.
- Affiliations
- Division of Cardiology, Wake Forest Baptist Health, Winston-Salem, North Carolina, US
- CGH Medical Center, Sterling, Illinois, US; Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, US
- Venue
- European Cardiology Review
- Publisher
- Radcliffe Medical Media Ltd
- Published
- 2023-09-28
- Volume
- 18
- ISSN
- 1758-3764
- 1758-3756
- PMC
- PMC10583159
- Cited by
- 33
- References
- 52
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

